Please ensure Javascript is enabled for purposes of website accessibility
Home / Products / Super-Affinity Antibody

Mouse Anti-Plasmodium berghei CSP Antibody (SAb2279)

Catalog #:   RXX55206 Specific References (50) DATASHEET
Host species: Mouse
Isotype: IgG2a, kappa
Applications: ELISA, Neutralization
Accession: P23093, P06915
Overview

Catalog No.

RXX55206

Species reactivity

Plasmodium berghei

Host species

Mouse

Isotype

IgG2a, kappa

Clonality

Monoclonal

Target

Circumsporozoite protein, CS, PbCSP, Circumsporozoite protein C-terminus, CSP

Concentration

2.95 mg/ml

Endotoxin level

Please contact with the lab for this information.

Purity

>95% as determined by SDS-PAGE.

Purification

Protein A/G purified from cell culture supernatant.

Accession

P23093, P06915

Applications

ELISA, Neutralization

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.

Clone ID

SAb2279

Data Image
References

Long lived liver-resident memory T cells of biased specificities for abundant sporozoite antigens drive malaria protection by radiation-attenuated sporozoite vaccination., PMID:40424562

Evidence for a model of conformational change by the Plasmodium falciparum circumsporozoite protein during sporozoite development in the mosquito host through the use of camelid single-domain antibodies., PMID:40293231

iDC-targeting PfCSP mRNA vaccine confers superior protection against Plasmodium compared to conventional mRNA., PMID:39971939

Late killing of Plasmodium berghei sporozoites in the liver by an anti-circumsporozoite protein antibody., PMID:39951341

Probing novel epitopes on the Plasmodium falciparum circumsporozoite protein for vaccine development., PMID:39557901

Immature dendritic cell-targeting mRNA vaccine expressing PfCSP enhances protective immune responses against Plasmodium liver infection., PMID:39041038

Non-clinical toxicity and immunogenicity evaluation of a Plasmodium vivax malaria vaccine using Poly-ICLC (Hiltonol®) as adjuvant., PMID:38448321

Establishing RTS,S/AS01 as a benchmark for comparison to next-generation malaria vaccines in a mouse model., PMID:38341502

Comparative analyses of functional antibody-mediated inhibition with anti-circumsporozoite monoclonal antibodies against transgenic Plasmodium berghei., PMID:37936181

Protective antibody threshold of RTS,S/AS01 malaria vaccine correlates antigen and adjuvant dose in mouse model., PMID:37563255

A genetically modified Plasmodium berghei parasite as a surrogate for whole-sporozoite vaccination against P. vivax malaria., PMID:36526627

The P. falciparum CSP repeat region contains three distinct epitopes required for protection by antibodies in vivo., PMID:34748617

Plasmodium Preerythrocytic Vaccine Antigens Enhance Sterile Protection in Mice Induced by Circumsporozoite Protein., PMID:34310889

Strategic Variants of CSP Delivered as SynDNA Vaccines Demonstrate Heterogeneity of Immunogenicity and Protection from Plasmodium Infection in a Murine Model., PMID:34152830

Avid binding by B cells to the Plasmodium circumsporozoite protein repeat suppresses responses to protective subdominant epitopes., PMID:33852850

Structural ordering of the Plasmodium berghei circumsporozoite protein repeats by inhibitory antibody 3D11., PMID:33253113

Importance of the Immunodominant CD8+ T Cell Epitope of Plasmodium berghei Circumsporozoite Protein in Parasite- and Vaccine-Induced Protection., PMID:32719159

A Multistage Formulation Based on Full-Length CSP and AMA-1 Ectodomain of Plasmodium vivax Induces High Antibody Titers and T-cells and Partially Protects Mice Challenged with a Transgenic Plasmodium berghei Parasite., PMID:32560380

A double-blind, placebo-controlled phase 1/2a trial of the genetically attenuated malaria vaccine PfSPZ-GA1., PMID:32434847

An open-label phase 1/2a trial of a genetically modified rodent malaria parasite for immunization against Plasmodium falciparum malaria., PMID:32434846

Protective efficacy of peptides from Plasmodium vivax circumsporozoite protein., PMID:32402755

Protective Malaria Vaccine in Mice Based on the Plasmodium vivax Circumsporozoite Protein Fused with the Mumps Nucleocapsid Protein., PMID:32325874

Characterization of two in vivo challenge models to measure functional activity of monoclonal antibodies to Plasmodium falciparum circumsporozoite protein., PMID:32183833

Design and assessment of TRAP-CSP fusion antigens as effective malaria vaccines., PMID:31967991

Optimization of an in vivo model to study immunity to Plasmodium falciparum pre-erythrocytic stages., PMID:31849326

Irradiated sporozoite vaccination induces sex-specific immune responses and protection against malaria in mice., PMID:31262583

Cytotoxic anti-circumsporozoite antibodies target malaria sporozoites in the host skin., PMID:30349082

Tailoring a Plasmodium vivax Vaccine To Enhance Efficacy through a Combination of a CSP Virus-Like Particle and TRAP Viral Vectors., PMID:29986894

Prime-boost vaccination with recombinant protein and adenovirus-vector expressing Plasmodium vivax circumsporozoite protein (CSP) partially protects mice against Pb/Pv sporozoite challenge., PMID:29348479

An in vitro assay to measure antibody-mediated inhibition of P. berghei sporozoite invasion against P. falciparum antigens., PMID:29209029

Natural Parasite Exposure Induces Protective Human Anti-Malarial Antibodies., PMID:29195810

Rare PfCSP C-terminal antibodies induced by live sporozoite vaccination are ineffective against malaria infection., PMID:29167197

Vaccine Containing the Three Allelic Variants of the Plasmodium vivax Circumsporozoite Antigen Induces Protection in Mice after Challenge with a Transgenic Rodent Malaria Parasite., PMID:29075260

Rational development of a protective P. vivax vaccine evaluated with transgenic rodent parasite challenge models., PMID:28417968

Extended protection capabilities of an immature dendritic-cell targeting malaria sporozoite vaccine., PMID:28342669

Rhesus macaque and mouse models for down-selecting circumsporozoite protein based malaria vaccines differ significantly in immunogenicity and functional outcomes., PMID:28288639

Identification of Novel Pre-Erythrocytic Malaria Antigen Candidates for Combination Vaccines with Circumsporozoite Protein., PMID:27434123

Development of a Plasmodium berghei transgenic parasite expressing the full-length Plasmodium vivax circumsporozoite VK247 protein for testing vaccine efficacy in a murine model., PMID:27129682

Tailoring a Combination Preerythrocytic Malaria Vaccine., PMID:26667840

IgG2 antibodies against a clinical grade Plasmodium falciparum CSP vaccine antigen associate with protection against transgenic sporozoite challenge in mice., PMID:25343487

A full-length Plasmodium falciparum recombinant circumsporozoite protein expressed by Pseudomonas fluorescens platform as a malaria vaccine candidate., PMID:25247295

Depletion of regulatory T cells augments a vaccine-induced T effector cell response against the liver-stage of malaria but fails to increase memory., PMID:25115805

Vectored antibody gene delivery protects against Plasmodium falciparum sporozoite challenge in mice., PMID:25114213

The ETRAMP family member SEP2 is expressed throughout Plasmodium berghei life cycle and is released during sporozoite gliding motility., PMID:23840634

Anopheles gambiae circumsporozoite protein-binding protein facilitates plasmodium infection of mosquito salivary glands., PMID:23801601

Development of a chimeric Plasmodium berghei strain expressing the repeat region of the P. vivax circumsporozoite protein for in vivo evaluation of vaccine efficacy., PMID:23716612

Mechanisms of protective immune responses induced by the Plasmodium falciparum circumsporozoite protein-based, self-assembling protein nanoparticle vaccine., PMID:23607541

Transgenic parasites stably expressing full-length Plasmodium falciparum circumsporozoite protein as a model for vaccine down-selection in mice using sterile protection as an endpoint., PMID:23536694

Full-length Plasmodium falciparum circumsporozoite protein administered with long-chain poly(I·C) or the Toll-like receptor 4 agonist glucopyranosyl lipid adjuvant-stable emulsion elicits potent antibody and CD4+ T cell immunity and protection in mice., PMID:23275094

Plasmodium berghei sporozoite challenge of vaccinated BALB/c mice leads to the induction of humoral immunity and improved function of CD8(+) memory T cells., PMID:23229763

Datasheet
$ 372
Product specifications
100 μg 372 1 mg 1860

Contact Information

Order: order@antibodysystem.com

Mail: support@antibodysystem.com

Distributor list

For research use only. Not for human or drug use.

Need help with your order?

Find out more about placing an order here

Mouse Anti-Plasmodium berghei CSP Antibody (SAb2279) [RXX55206]
Terms of sale Website terms of use Cookie policy Privacy
Copyright © 2025 AntibodySystem SAS. All Rights Reserved.            All Products are for Research Use Only